Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Persistence of HIV-1 transmitted drug resistance mutations

Hannah Castro et al. J Infect Dis. .

Abstract

There are few data on the persistence of individual human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) mutations in the absence of selective drug pressure. We studied 313 patients in whom TDR mutations were detected at their first resistance test and who had a subsequent test performed while ART-naive. The rate at which mutations became undetectable was estimated using exponential regression accounting for interval censoring. Most thymidine analogue mutations (TAMs) and T215 revertants (but not T215F/Y) were found to be highly stable, with NNRTI and PI mutations being relatively less persistent. Our estimates are important for informing HIV transmission models.

Keywords: HIV-1; mutations; persistence; resistance; transmitted.

PubMed Disclaimer

References

    1. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363–71. - PubMed
    1. Jain V, Sucupira MC, Bacchetti P, et al. Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes. J Infect Dis. 2011;203:1174–81. - PMC - PubMed
    1. Little SJ, Frost SDW, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82:5510–8. - PMC - PubMed
    1. Pingen M, Nijhuis M, de Bruijn JA, Boucher CAB, Wensing AMJ. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother. 2011;66:1467–80. - PubMed
    1. van Maarseveen NM, Wensing AM, de Jong D, et al. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis. 2007;195:399–409. - PubMed

Publication types

Substances